Hu et al. treated one patient with R/R AML in a phase I trial of anti-CD7 CAR-T cells in hematological malignancies, with a CR 28 days after CAR-T cell infusion; no life-threatening toxicity was observed [76]. This evidence concerns the gene CD7 and acute myeloid leukemia.